

GENOME THERAPEUTICS CORP
Form 8-K
November 08, 2001

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 8, 2001

GENOME THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

MASSACHUSETTS

0-10824

04-2297484

(State or other jurisdiction
of incorporation)

(Commission File Number)

(I.R.S. Employer
Identification Number)

100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453

(Address, of principal executive offices, including zip code)

(781) 398-2300

(Registrant's Telephone number including area code)

PAGE 1 OF 4 PAGES.

Item 5. OTHER EVENTS

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

On November 8, 2001, Genome Therapeutics Corp. issued a press release announcing its financial results for the 3-month and 12-month periods ended August 31, 2001, as well as a change in Genome's reporting schedule from an August 31 year end to a December 31 year end. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By /s/ Stephen Cohen

Name: Stephen Cohen
Title: Chief Financial Officer

Date: November 8, 2001

-3-

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

EXHIBIT INDEX

99.1 Press Release dated November 8, 2001